Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris

 Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris

Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris

Shots:
  • Glenmark to receive upfront, milestones and royalties on sales from Yuhan. Yuhan to get exclusive commercialization rights for Glenmark’s Ryaltris in South Korea
  • Yuhan will be responsible for its regulatory approval and Glenmark to take care of manufacturing and supply of Ryaltris in South Korea
  • Ryaltrisis a FD combination of anti-histamine and steroid i.e olopatadine hydrochloride (665 mcg) & mometasone furoate (25 mcg) indicated to treat symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age. In May 2018 Glenmark filled Ryaltris’ NDA to the US FDA and is currently reviewed

Click here to read full press release/ article | Ref: Glenmark | Image: DNA India

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post